Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CLDX - Celldex Therapeutics, Inc.
Market Cap 1.63B P/E - EPS this Y 15.40% Ern Qtrly Grth -
Income -150.22M Forward P/E -11.59 EPS next Y -19.00% 50D Avg Chg -2.00%
Sales 8.3M PEG - EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 5.37 EPS next 5Y - 52W High Chg -29.00%
Recommedations 1.80 Quick Ratio 29.06 Shares Outstanding 66.29M 52W Low Chg 27.00%
Insider Own 0.30% ROA -17.83% Shares Float 66.10M Beta 1.56
Inst Own 107.22% ROE -27.53% Shares Shorted/Prior 8.41M/8.66M Price 34.43
Gross Margin - Profit Margin - Avg. Volume 445,538 Target Price 67.11
Oper. Margin -1,854.16% Earnings Date Oct 31 Volume 310,948 Change -0.95%
Healthcare | Biotechnology | United States
About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc. News
12/19/24 Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
12/12/24 Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
11/20/24 Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
11/11/24 Celldex Therapeutics to Present at Upcoming Investor Conferences
11/08/24 Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/06/24 Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
11/06/24 Celldex: Q3 Earnings Snapshot
11/06/24 Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/29/24 Celldex selloff creates buying opportunity, says Guggenheim
10/28/24 Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years
10/26/24 Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
10/25/24 Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
07:39 AM Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results
10/15/24 Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks
09/26/24 CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
09/25/24 Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
09/16/24 Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
09/14/24 Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock
08/10/24 Celldex Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/08/24 Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Young Diane C. SVP, CHIEF MEDICAL O.. SVP, CHIEF MEDICAL OFFICER Aug 17 Option 6.55 64,000 419,200 47,115 08/19/22
Young Diane C. SVP, CHIEF MEDICAL O.. SVP, CHIEF MEDICAL OFFICER Aug 17 Sell 37.3 19,000 708,700 2,115 08/19/22